REMS Communications Could Get Refreshed After Advisory Panel Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Risk Communications Advisory Committee will address methods for presenting REMS information and assessing whether it is reaching the target population.
You may also be interested in...
REMS Modification Guidance Coming As FDA Rejects Petition For Shared REMS Rules
Agency will wait until it has more experience with shared REMS before deciding whether to issue regulations or guidance on their implementation, but for now it hopes sponsors can work out problems on their own.
REMS Modification Studies Could Use Foreign Markets As Controls
A look at the safety record of a drug in foreign countries where REMS elements are not in play could differentiate the impact of a REMS compared to other risk management efforts, Amgen suggests.
How To Speak REMS: Structured Product Labeling Seen As Route To Standardization
“Before we can standardize REMS we need to have that common language to describe what’s in the REMS,” FDA’s Adam Kroetsch says.